Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Novo Nordisk A/S
- Study ID
- NCT03926117
- Phase
- PHASE2
- Status
- Completed
Conditions
- Chronic Kidney Diseases
- Inflammation
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Ziltivekimab — BIOLOGICALhuman IgG1k anti-human IL-6 monoclonal antibody
Study Details
Patients with chronic kidney disease, who have evidence of systemic inflammation with increased cardiovascular risk, will be enrolled into this trial. The purpose of this trial is to determine a dose to select for a potential cardiovascular outcome trial with Ziltivekimab. Doses to be tested will be 7.5 mg, 15 mg and 30 mg subcutaneous monthly compared to placebo for six months.
Key Dates
- Start date
- Jun 3, 2019
- Status verified
- Dec 2025
- Primary completion
- Jun 26, 2020
- Completion
- Jun 26, 2020
Study Design
- Enrollment
- 264 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Placebo Comparator: PlaceboMatching placebo
- Experimental: Ziltivekimab 7.5 mg
- Experimental: Ziltivekimab 15 mg
- Experimental: Ziltivekimab 30 mg
Primary Outcome Measure
Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) Levels [ Time Frame: Baseline (average of the hs-CRP value prior to randomization and day 1), week 13 ]
Locations (49)
Find similar trials in Birmingham, AL
Related Studies
- Evaluation and Long-Term Follow-up of Patients With Inflammatory DisordersEnrolling By Invitation · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
- Immune Cell Response to StimuliRecruiting · National Institute of Environmental Health Sciences (NIEHS) · Research Triangle Park, North Carolina
- Diagnosis and Management of Inflammatory and Infectious DiseasesRecruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
- BLOOM: Biological Legacy of Origin in Mother-Infant DyadsRecruiting · University of Miami · Miami, Florida